By Colin Kellaher
Bayer has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its kidney-disease drug Kerendia in certain people with heart failure.
Bayer on Monday said the application covers Kerendia for the treatment of adults with heart failure with a left ventricular ejection fraction, or LVEF, of at least 40%, also known as mildly reduced or preserved LVEF.
The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period.
German drugs-to-crops giant Bayer said about 6.7 million adults in the U.S. live with heart failure, with roughly 55% having mildly reduced or preserved LVEF.
The FDA approved Kerendia in 2021 to improve cardiovascular outcomes for patients with type 2 diabetes and chronic kidney disease. The drug generated sales of around $500 million last year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 17, 2025 06:36 ET (10:36 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。